Wang, W., Zhang, W., Su, L., Liu, L., Gao, Y., Wang, Q., Su, H., Song, Y., Zhang, H., Shen, J., Jing, H., Wang, S., Cen, X., Liu, H., Liu, A., Li, Z., Luo, J., He, J., Wang, J., … Zhou, D. (2024). Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China. Annals of Hematology, 103(8), 3061–3069. https://doi.org/10.1007/s00277-024-05708-w

Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., Drake, C. G., Fizazi, K., Piulats, J. M., Wysocki, P. J., Buchschacher, G. L., Alekseev, B., Mellado, B., Karaszewska, B., Doss, J. F., Rasuo, G., Datye, A., Mariathasan, S., Williams, P., & Sweeney, C. J. (2022). Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine, 28(1), 144–153. https://doi.org/10.1038/s41591-021-01600-6